The Effect of a Selective Inhibitor of Phosphodiesterase-9 on Oxidative Stress, Inflammation and Cytotoxicity in Neutrophils from Patients with Sickle Cell Anaemia

Basic and Clinical Pharmacology and Toxicology

Volumn 118, Issue 4, 2016, Pages 271-278

  Barbosa, Maritza Cavalcante ^a   de Jesus dos Santos, Talyta Ellen ^a   Santos, Thayna Nogueira dos ^a   Pedrosa, Alano Martins ^a   Elias, Darcielle Bruna Dias ^a   Leal, Luzia Kalyne Almeida Moreira ^a   de Araújo Lopes, Amanda ^a   Sasahara, Greyce Luri ^a   Gonçalves Lemes, Romélia Pinheiro ^a  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BAY 73 6691; BIOLOGICAL MARKER; CATALASE; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; MYELOPEROXIDASE; NITRIC OXIDE; PHOSPHODIESTERASE; PHOSPHODIESTERASE 9; PHOSPHODIESTERASE 9 INHIBITOR; PHOSPHODIESTERASE INHIBITOR; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BAY 73-6691; PEROXIDASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; TUMOR NECROSIS FACTOR;

ADULT; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BIOAVAILABILITY; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; INFLAMMATION; LIPID PEROXIDATION; MALE; MOLECULAR DIAGNOSIS; NEUTROPHIL; OXIDATIVE STRESS; PRIORITY JOURNAL; SICKLE CELL ANEMIA; BLOOD; CELL SURVIVAL; DRUG EFFECTS; ENZYMOLOGY; IMMUNOLOGY; METABOLISM;

ADULT; ANEMIA, SICKLE CELL; BIOMARKERS; CELL SURVIVAL; FEMALE; HUMANS; INFLAMMATION; MALE; NEUTROPHILS; NITRIC OXIDE; OXIDATIVE STRESS; PEROXIDASE; PHOSPHODIESTERASE INHIBITORS; PYRAZOLES; PYRIMIDINES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84962978222     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12487     Document Type: Article

References (53)

1. Stuart MJ, Nagel RL. Sickle-cell disease. Lancet 2004;364:1343-60.
2. Belcher JD, Beckman JD, Balla G, Balla J, Vercellotti G. Heme degradation and vascular injury. Antioxid Redox Signal 2010;12:233-48.
3. Frenette PS. Sickle cell vaso-occlusion: multistep and multicellular paradigm. Curr Opin Hematol 2003;9:101-6.
4. Belcher JD, Bryant CJ, Nguyen J. Transgenic sickle mice have vascular inflammation. Blood 2003;101:3953-9.
5. Belcher JD, Mahaseth H, Welch TE. Critical role of endothelial cell activation in hypoxia-induced vasoocclusion in transgenic sickle mice. Am J Physiol Heart Circ Physiol 2005;288:2715-25.
6. Ohene-Frempong K, Weiner SJ, Sleeper LA, Miller ST, Embury S, Moohr JW et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998;91:288-94.
7. Castro O, Brambilla DJ, Thorington B, Reindorf CA, Scott RB, Gillette P et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood 1994;84:643-9.
8. Chiang EY, Frenette PS. Sickle cell vaso-occlusion. Hematol Oncol Clin North Am 2005;19:771-84.
9. Lard LR, Mul FP, de Haas M, Roos D, Duits AJ. Neutrophil activation in sickle cell disease. J Leukoc Biol 1999;66:411-5.
10. Akerley WL, Guyre PM, Davis BH. Neutrophil activation through high-affinity Fc gamma receptor using a monomeric antibody with unique properties. Blood 1991;77:607-15.
11. Mack AK, Kato GJ. Sickle cell disease and nitric oxide: a paradigm shift? Int J Biochem Cell Biol 2006;38:1237-43.
12. Wood KC, Granger DN. Sickle cell disease: role of reactive oxygen and nitrogen metabolites. Clin Exp Pharmacol Physiol 2007;34:926-32.
13. Walter PB, Fung EB, Killilea DW, Jiang Q, Hudes M, Madden J et al. Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. Br J Haematol 2006;135:254-63.
14. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-12.
15. Abraham E. NF-kappaB activation. Crit Care Med 2000;28:100-4.
16. Beckman JS, Crow JP. Pathological implications of nitric oxide, superoxide and peroxynitrite formation. Biochem Soc Trans 1993;21:330-4.
17. Durante W, Kroll MH, Christodoulides N, Peyton KJ, Schafer AI. Nitric oxide induces heme oxygenase-1 gene expression and carbon monoxide production in vascular smooth muscle cells. Circ Res 1997;80:557-64.
18. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006;58:488-520.
19. Almeida CB, Traina F, Lanaro C. High expression of the cGMP-specific phosphodiesterase, PDE9A, in sickle cell disease (SCD) and the effects of its inhibition in erythroid cells and SCD neutrophils. Br J Haematol 2008;142:836-44.
20. Canalli AA, Franco-Penteado CF, Saad STO, Conran N, Costa FF. Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation. Haematologica 2008;93:605-9.
21. Miguel LI, Almeida CB, Traina F. Inhibition of phosphodiesterase 9A (PDE9A) reduces cytokine-stimulated in vitro adhesion of neutrophils from sickle cell anaemia individuals. Inflamm Res 2011;60:633-42.
22. Almeida CB, Scheiermann C, Jang JE, Prophete C, Costa F, Conran N et al. Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice. Blood 2012;120:2879-88.
23. Ballas SK. More definitions in sickle cell disease: steady state v base line data. Am J Hematol 2012;87:338.
24. Lucisano YM, Mantovani B. Lysosomal enzyme release from polymorphonuclear leukocytes induced by immune complexes of IgM and IgG. J Immunol 1984;132:2015-20.
25. Kayeba LM, Kanashiro A, Azzolini AECS, Soriani FM, Lopes JLC, Lucisano-Valim YM. Inhibitory effect of eight simple coumarins on the lucigenin enhanced chemiluminescence of rabbit neutrophils. Res Commun Mol Pathol Pharmacol 2002;111:103-14.
26. Green LC, De Luzuriaga KR, Wagner DA, Rand W, Istfan N, Young VR et al. Nitrate biosynthesis in man. Proc Natl Acad Sci USA 1981;78:7764-8.
27. Draper HH, Hadley M. Malondialdehyde determination as index of lipid peroxidation. Methods Enzymol 1990;186:421-31.
28. Aebi H. Catalase in vitro. Methods Enzymol 1984;105:121-6.
29. Mosmann T. Rapid colorimetric assay of cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
30. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV. Effect of hydroxyurea on the frequency of painful crises in sickle cell anaemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anaemia. N Engl J Med 1997;332:1317-22.
31. Cokic VP, Smith RD, Beleslin-Cokic BB, Njoroge JM, Miller JL, Gladwin MT. Hydroxyurea induces fetal hemoglobin by the nitric oxide dependent activation of soluble guanylyl cyclase. J Clin Invest 2003;111:231-9.
32. Ikuta T, Ausenda S, Cappellini MD. Mechanism for fetal globin gene expression: role of the soluble guanylate cyclase-cGMP-dependent protein kinase pathway. Proc Natl Acad Sci USA 2001;98:1847-52.
33. Nahavandi M, Tavakkoli F, Wyche MQ, Perlin E, Winter WP, Castro O. Nitric Oxide and cyclic GMP levels in sickle cell patients receiving hydroxyurea. Br J Haematol 2002;119:855-7.
34. King SB. Serial review: mechanisms and novel directions in the biological applications of nitric oxide donors. Free Radic Biol Med 2004;37:737-44.
35. Huang J, Hadimani SB, Rupon JW, Ballas SK, Kim-Shapiro DB, King SB. Iron nitrosyl hemoglobin formation from the reactions of hydroxyurea and hemoglobin. Biochemistry 2006;41:2466-74.
36. Huang J, Kim-Shapiro DB, King SB. Catalase-mediated nitric oxide formation from hydroxyurea. J Med Chem 2004;47:3495-501.
37. Aslan M, Ryan T, Adler B, Townes T, Parks D, Thompson J et al. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci USA 2001;98:15215-20.
38. Hebbel RP, Eaton JW, Balasingam M, Steinberg MH. Spontaneous oxygen radical generation by sickle erythrocytes. J Clin Invest 1982;70:1253-9.
39. Silva DGH, Belini-Junior E, Carrocini GCS, Torres LS, Ricci-Júnior O, Lobo CLC et al. Genetic and biochemical markers of hydroxyurea therapeutic response in sickle cell anaemia. Genet Mol Res 2013;14:108.
40. Carvalho-dos Santos BS, Dias-Elias DB, Silva-Rocha LB, Barbosa MC, Gonçalves RP. Impact of bS-globin haplotypes on oxidative stress in patients with sickle cell anaemia in steady state. Arch Med Res 2012;43:536-40.
41. Elias DBD, Freitas RM, Gonçalves RP, Magalhães HYF, Sousa JH, Magalhães SMM. Evaluation of the concentration of malondialdehyde and nitrite in patients with sickle cell anaemia treated or not with hydroxyurea. Einstein 2010;8:414-8.
42. Asian M, Thomley BD, Freeman BA. Reactive species in sickle cell disease. Ann N Y Acad Sci 2000;899:375-91.
43. Johnson RM, Goyette G, Ravindranath Y, Ho YS. Hemoglobin autoxidation and regulation of endogenous H2O2 levels in erythrocytes. Free Radic Biol Med 2005;39:1407-17.
44. Amer J, Ghoti H, Rachmilewitz E, Koren A, Levin C, Fibach E. Red blood cells, platelets and polymorphonuclear neutrophils of patients with sickle cell disease exhibit oxidative stress that can be ameliorated by antioxidants. Br J Haematol 2005;132:108-13.
45. Solovey A, Kollander R, Shet A. Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood 2004;104:840-6.
46. Traber MG, Stevens JF. Vitamins C and E: beneficial effects from a mechanistic perspective. Free Radic Biol Med 2011;51:1000-13.
47. Martins VD, Manfredini V, Peralba MC, Benfato MS. Alpha-lipoic acid modifies oxidative stress parameters in sickle cell trait subjects and sickle cell patients. Clin Nutr 2009;28:192-7.
48. Arruda MM, Mecabo G, Rodrigues CA, Matsuda SS, Rabelo IB, Figueiredo MS. Antioxidant vitamins C and E supplementation increases markers of haemolysis in sickle cell anaemia patients: a randomized, double-blind, placebo-controlled trial. Br J Haematol 2013;160:688-700.
49. Bourantas K, Dalekos GN, Makis A, Chaidos A, Tsiara S, Mavrides A. Cytokines and acute-phase proteins during the steady state of sickle cell disease. Eur J Hematol 1998;61:49-54.
50. Raghupathy R, Haider MZ, Azizieh F, Abdelsalam A, D'sousa TM, Adekile AD. Th1 and Th2 cytokine profiles in sickle cell disease. Acta Haematol 2000;103:197-9.
51. Conran N, Saad STO, Costa FF, Ikuta T. Leukocyte numbers correlate with plasma levels of granulocyte-macrophage colony-stimulating factor in sickle cell disease. Ann Hematol 2007;86:255-61.
52. Aslan M, Canatan D. Modulation of redox pathways in neutrophils from sickle cell disease patients. Exp Hematol 2008;36:1535-44.
53. Vilas-Boas W, Cerqueira BAV, Zanette AMD, Reis MG, Barral-Netto M. Arginase levels and their association with Th17-related cytokines, soluble adhesion molecules (sICAM-1 and sVCAM-1) and hemolysis markers among steady-state sickle cell anemia patients. Ann Haematol 2010;89:877-82.